2.89

2.03% -0.06

Pre-market: 2.91 0.02 +0.69%

Maravai Lifesciences Holdings Inc (MRVI)

Overview News Price History Option Chain Financials Why MRVI Down? Discussions Forecast

Maravai Lifesciences Holdings Inc stock is traded at $2.89, with a volume of 2.05M. It is down -2.03% in the last 24 hours and down -18.59% over the past month. Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.

Previous Close:

$2.95

Open:

$2.92

24h Volume:

2.05M

Relative Volume:

1.45

Market Cap:

$423.05M

Revenue:

$185.74M

Net Income/Loss:

$-230.76M

P/E Ratio:

-3.1902

EPS:

-0.9059

Net Cash Flow:

$-70.72M

1W Performance:

+2.12%

1M Performance:

-18.59%

6M Performance:

-12.69%

1Y Performance:

+45.23%

1-Day Range:

$2.815

$2.941

1-Week Range:

$2.80

$3.055

52-Week Range:

$1.665

$4.105

Maravai Lifesciences Holdings Inc Stock (MRVI) Company Profile

Name

Maravai Lifesciences Holdings Inc

Sector

Healthcare (1110)

Industry

Biotechnology (624)

Phone

(858) 546-0004

Address

10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO

Employee

435

Twitter

Next Earnings Date

2025-03-18

Latest SEC Filings

MRVI's Discussions on Twitter

Compare MRVI vs VRTX, REGN, ARGX, ALNY, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MRVI Maravai Lifesciences Holdings Inc	2.89	423.05M	185.74M	-230.76M	-70.72M	-0.9059
VRTX Vertex Pharmaceuticals Inc	431.86	109.85B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	760.27	80.38B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	765.43	47.60B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	319.52	42.63B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	163.03	35.19B	606.42M	-1.28B	-997.58M	-6.403

Maravai Lifesciences Holdings Inc Stock (MRVI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-26-25	Downgrade	Robert W. Baird	Outperform → Neutral
Dec-19-24	Initiated	Guggenheim	Neutral
Dec-05-24	Downgrade	Goldman	Neutral → Sell
Nov-14-24	Initiated	Wolfe Research	Peer Perform
Nov-08-24	Downgrade	William Blair	Outperform → Mkt Perform
Aug-28-24	Initiated	Wells Fargo	Overweight
Aug-13-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Apr-10-24	Initiated	Craig Hallum	Buy
Dec-12-23	Upgrade	BofA Securities	Neutral → Buy
Aug-08-23	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
May-23-23	Downgrade	Credit Suisse	Outperform → Neutral
May-09-23	Downgrade	Goldman	Buy → Neutral
Jan-05-23	Downgrade	UBS	Buy → Neutral
Dec-14-22	Initiated	Deutsche Bank	Buy
Dec-07-22	Initiated	RBC Capital Mkts	Outperform
Nov-03-22	Downgrade	BofA Securities	Buy → Neutral
Aug-25-22	Initiated	Credit Suisse	Outperform
Aug-05-21	Resumed	Credit Suisse	Outperform
Dec-16-20	Initiated	KeyBanc Capital Markets	Overweight
Dec-15-20	Initiated	BofA Securities	Buy
Dec-15-20	Initiated	Credit Suisse	Outperform
Dec-15-20	Initiated	Goldman	Buy
Dec-15-20	Initiated	Jefferies	Buy
Dec-15-20	Initiated	Robert W. Baird	Outperform
Dec-15-20	Initiated	Stifel	Buy
Dec-15-20	Initiated	William Blair	Outperform
Dec-14-20	Initiated	UBS	Buy

View All

Maravai Lifesciences Holdings Inc Stock (MRVI) Latest News

Apr 06, 2026